Lupin Limited has informed the Exchange regarding a press release dated April 24, 2025, titled "Lupin Receives Approval from U.S. FDA for Tolvaptan Tablets".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited has received approval from the U.S. FDA for its Tolvaptan Tablets, as announced in a press release dated April 24, 2025. Tolvaptan is used to treat conditions like hyponatremia (low blood sodium) and autosomal dominant polycystic kidney disease (ADPKD). The approval allows Lupin to manufacture and market this generic drug in the United States. This adds another product to Lupin's portfolio of U.S. FDA-approved medications, strengthening its presence in the lucrative U.S. generic pharmaceutical market. The U.S. is one of the largest generic drug markets globally, and approvals like these typically translate into meaningful revenue contributions.
Positive for shareholders — U.S. FDA approvals are key growth drivers for Indian pharma companies, and this launch is likely to support Lupin's U.S. revenue. The news may generate short-term positive sentiment around the stock.